Clinical Trial: CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL



Official Title: A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)

Brief Summary:

The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes.

The names of the study drugs involved in this study are:

  • CB-103 (an oral NOTCH pathway inhibitor)
  • Abemaciclib (CDK4/6 inhibitor)
  • Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))